Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Pneumonia Age: Adult Condition: Moderate-to-severe pneumonia (not caused by Pseudomonas) |
Dose: Intravenous – 1-2 g Frequency: every 8-12 hours Duration: 7-10 days |
|
Indication: Pneumonia Age: Adult Condition: Moderate-to-severe pneumonia (caused by Pseudomonas) |
Dose: Intravenous – 1-2 g Frequency: every 8-12 hours Duration: up to 21 days |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Febrile Neutropenia Age: Child: greater than 2 months Condition: Empiric therapy in febrile neutropenic patients |
Dose: Intravenous – 50 mg/kg Frequency: every 8 hours Duration: for 7 days or until neutropenia resolves Note: not to exceed 2 g every 8 hours |
|
Indication: Pneumonia Age: Child Condition: Treatment of moderate-to-severe pneumonia |
Dose: Intravenous – 50 mg/kg Frequency: every 12 hours Duration: for 10 days Note: not to exceed 2 g every 12 hours |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment with Creatinine Clearance greater than 60 mL/min |
Dose: 500 mg Frequency: every 12 hours Note: Recommended maintenance dosage 500 mg every 12 hours |
|
Condition: Renal impairment with Creatinine Clearance 30-60 mL/min |
Dose: 500 mg Frequency: every 24 hours Note: Recommended maintenance dosage 500 mg every 12 hours |
Administration
- For hospital use only
- Must be administered by healthcare professional
Side Effect
- Positive Coombs test result without hemolysis (16%)
- Rash (1-4%)
- Elevated alanine aminotransferase (3%)
- Hypophosphatemia (3%)
- Diarrhea (Less than 3%)
- Eosinophilia (2%)
- Erythema at injection site (2%)
- Normal partial thromboplastin time (PTT) (2%)
- Nausea or vomiting (Less than 2%)
- Fever (1%)
- Headache (1%)
- Pain (1%)
- Agranulocytosis
- Anaphylactic shock
- Anaphylaxis
- Coma
- Encephalopathy
- Hallucinations
- Leukopenia
- Myoclonus
- Neuromuscular excitability
- Neutropenia
- Seizures
- Thrombocytopenia
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Aminoglycosides
|
Increased potential for nephrotoxicity and ototoxicity
|
|
Potent Diuretics (Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolazone, Bumetanide, Ethacrynic acid, Furosemide, Torsemide, Amiloride, Eplerenone, Spironolactone, Triamterene)
|
Increased risk of nephrotoxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for allergic reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Do not use later than the date of expiry. Keep all medicines out of the reach of children. To be dispensed only on the prescription of a registered physician.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.